New Drug Dossier - Medical Marketing and Media

MM&M's New Drug Dossier combines promotional insights with clinical information to offer marketers the first complete online resource for newly approved drugs. Each dossier features agency rosters, marketing strategy, recent news coverage, clinical insights from Monthly Prescribing Reference (MPR), market data from IMS Health, physician outlook from the GfK US Healthcare Companies and late-stage pipeline candidates from Adis R&D Insight.

For more information or to subscribe click here »

SAMPLE DOSSIER: Vyvanse

November 21, 2007

Shire's marketing strategy with Vyvanse involves converting patients from category leader Adderall XR over to the new drug, which launched in June after its February approval to treat symptoms of ADHD in children aged 6 to 12.

FULL DRUG INDEX

Adcetris

Adcirca

Afinitor

Afluria

Akten

Altabax

Alvesco

Angeliq

Arcalyst

Arzerra

Azasite

Azor

Banzel

Brovana

Bystolic

Calomist

Cimzia

Cleviprex

Combigan

Complera

Daliresp

Dificid

Divigel

Doribax

Edurant

Effient

Egrifta

Elestrin

Endometrin

Entereg

Epiduo Gel

Evamist

Exforge 5/160

Eylea

Fanapt

Feraheme

Fexmid

Flector Patch

Fosteum

Fusilev

Gilenya

Halaven

Ibudone

Implanon

Incivek

Intelence

Invega

Invega Sustenna

Isentress

Istodax

Ixempra

Ixiaro

Jakafi

Janumet

Jevtana

Juvisync

Kapidex

Kinrix

Kuvan

Latuda

Lexiscan

Lialda

Liquadd

Livalo

Lumizyme

Lusedra

Lybrel

Makena

Moxatag

Multaq

Natazia

Neupro

Nplate

Omnaris

Onfi

Onglyza

Ozurdex

Pataday

Patanase

PegIntron/REBETOL

Pentacel

Perforomist

Pradaxa

PrandiMet

Pristiq

Prolia

Promacta

Pylera

Reclast

Recothrom

Relistor

Renvela

RiaSTAP

Rotarix

Samsca

Saphris

Savella

Selzentry

Simcor

Simponi

Most Recent Approvals

Jakafi

December 30, 2011

Incyte's marketing strategy for Jakafi includes a mix of direct and non-personal selling tactics designed, first and foremost, to increase awareness and education. By and large, clinicians are not too familiar with Jakafi ahead of the launch.

Eylea

December 05, 2011

The launch strategy for Eylea includes a commercial team of over 125 people trained to educate retinal specialists in use of this new, more convenient option for treating macular degeneration.

Onfi

November 21, 2011

This oral therapy, which treats a challenging form of epilepsy, will be marketed via a specialty sales force and a targeted marketing campaign.

Juvisync

October 31, 2011

Merck's latest diabetes product offers something different in the metabolics space: the only pill packing a DPP-IV inhibitor (Januvia) and, for diabetics who need its lipid-lowering ability, a statin (Zocor).

Adcetris

October 31, 2011

Seattle Genetics has been running professional disease-awareness advertising at medical congresses to upend a popular myth about Hodgkin's disease therapy.

Complera

October 11, 2011

With Complera's approval, Gilead finds itself in the enviable position of marketing another once-a-day HIV combo pill. Complera packages together Truvada, itself a combination of two drugs, with J&J's Edurant.

Zelboraf

October 05, 2011

Three sales forces, including one each from Roche and its Molecular Diagnostics Business, are looking to penetrate the melanoma market for patients with BRAF mutations.

Yervoy

July 25, 2011

Yervoy communications will have a decidedly patient-centric tone, given the serious nature of melanoma, along with a focus on the drug's ability to maximize outcomes.

Dificid

July 06, 2011

Considering infectious disease specialists are among the heaviest users of the web during patient consults, a big part of the Dificid launch strategy involves digital promotion.